Sandra Ciesek

List of Publications by Citations

Source: https://exaly.com/author-pdf/3258735/sandra-ciesek-publications-by-citations.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169 papers	5,884 citations	38 h-index	73 g-index
202 ext. papers	7,954 ext. citations	8.5 avg, IF	6.31 L-index

#	Paper	IF	Citations
169	Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. *Nature*, **2020**, 583, 469-472	50.4	498
168	Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. *Nature*, **2020**, 587, 657-662	50.4	418
167	Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. *New England Journal of Medicine*, **2020**, 382, 1278-1280	59.2	397
166	A lymphotoxin-driven pathway to hepatocellular carcinoma. *Cancer Cell*, **2009**, 16, 295-308	24.3	306
165	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. *Hepatology*, **2011**, 54, 1947-55	11.2	207
164	Detection of SARS-CoV-2 in raw and treated wastewater in Germany - Suitability for COVID-19 surveillance and potential transmission risks. *Science of the Total Environment*, **2021**, 751, 141750	10.2	180
163	Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. *Journal of Virology*, **2010**, 84, 5751-63	6.6	174
162	Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. *Gastroenterology*, **2010**, 138, 1885-97	13.3	154
161	Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. *Immunity*, **2020**, 53, 442-455.e4	32.3	151
160	The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 2123-31	5.1	140
159	Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *Journal of Clinical Virology*, **2020**, 129, 104480	14.5	135
158	Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies		128
157	Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication. *Molecular Cell*, **2020**, 80, 164-174.e4	17.6	106
156	SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. *Cardiovascular Research*, **2020**, 116, 2207-2215	9.9	101
155	Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. *Hepatology*, **2009**, 50, 1638-45	11.2	96
154	Clinical performance of different SARS-CoV-2 IgG antibody tests. *Journal of Medical Virology*, **2020**, 92, 2243-2247	19.7	91
153	Lack of antiviral activity of darunavir against SARS-CoV-2. *International Journal of Infectious Diseases*, **2020**, 97, 7-10	10.5	87

152	The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. *Journal of Clinical Medicine*, **2021**, 10,	5.1	84
151	Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. *Scandinavian Journal of Gastroenterology*, **2011**, 46, 1092-8	2.4	80
150	Inactivation and survival of hepatitis C virus on inanimate surfaces. *Journal of Infectious Diseases*, **2011**, 204, 1830-8	7	80
149	Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. *Journal of Clinical Virology*, **2009**, 46, 210-5	14.5	74
148	An action plan for pan-European defence against new SARS-CoV-2 variants. *Lancet, The*, **2021**, 397, 469-470	170	67
147	SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission. *Transfusion*, **2020**, 60, 1119-1122	2.9	65
146	How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. *Journal of Infectious Diseases*, **2010**, 201, 1859-66	7	63
145	Glucocorticosteroids increase cell entry by hepatitis C virus. *Gastroenterology*, **2010**, 138, 1875-84	13.3	63
144	Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread?. *Journal of Clinical Virology*, **2021**, 135, 104713	14.5	62
143	GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. *Journal of Hepatology*, **2019**, 70, e81	13.4	54
142	Hepatitis in 2010: the dawn of a new era in HCV therapy. *Nature Reviews Gastroenterology and Hepatology*, **2011**, 8, 69-71	24.2	52
141	Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. *Journal of Infectious Diseases*, **2013**, 207, 281-7	7	50
140	Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections. *Lancet, The*, **2021**, 397, 92-93	40	48
139	Host cell mTORC1 is required for HCV RNA replication. *Gut*, **2016**, 65, 2017-2028	19.2	42
138	Aprotinin Inhibits SARS-CoV-2 Replication. *Cells*, **2020**, 9,	7.9	42
137	Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Journal of Infectious Diseases*, **2021**, 223, 56-61	7	42
136	Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection		41
135	Optimized qRT-PCR Approach for the Detection of Intra- and Extra-Cellular SARS-CoV-2 RNAs. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	40

134	Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles. *Journal of Virology*, **2011**, 85, 7613-21	6.6	39
133	Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2, Germany, March 2020. *Eurosurveillance*, **2020**, 25,	19.8	39
132	Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. *Transplant Infectious Disease*, **2016**, 18, 326-32	2.7	38
131	Immunosuppression, liver injury and post-transplant HCV recurrence. *Journal of Viral Hepatitis*, **2012**, 19, 1-8	3.4	37
130	Inactivation of hepatitis C virus infectivity by human breast milk. *Journal of Infectious Diseases*, **2013** , 208, 1943-52	7	37
129	Interferon-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. *Journal of Infectious Diseases*, **2012**, 205, 1351-62	7	37
128	Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. *Journal of Hepatology*, **2019**, 71, 301-312	13.4	34
127	Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using minipools of RNA prepared from routine respiratory samples. *Journal of Clinical Virology*, **2020**, 127, 104381	14.5	34
126	Influenza virus infection as precipitating event of acute-on-chronic liver failure. *Journal of Hepatology*, **2019**, 70, 797-799	13.4	34
125	SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles		33
124	Assessment of SARS-CoV-2 Transmission on an International Flight and Among a Tourist Group. *JAMA Network Open*, **2020**, 3, e2018044	10.4	31
123	Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors. *Discovery Medicine*, **2011**, 12, 237-44	2.5	31
122	A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. *Scientific Data*, **2021**, 8, 70	8.2	30
121	Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replication. *Gastroenterology*, **2012**, 143, 439-47.e1	13.3	28
120	Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. *Journal of Infectious Diseases*, **2008**, 197, 355-60	7	28
119	SARS-CoV-2 infected host cell proteomics reveal potential therapy targets		27
118	Second-wave protease inhibitors: choosing an heir. *Clinics in Liver Disease*, **2011**, 15, 597-609	4.6	26
117	Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro. *Journal of Infectious Diseases*, **2021**, 224, 1109-1114	7	26

116	Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication. *Current Opinion in Virology*, **2015**, 14, 56-61	7.5	25
115	Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARS-CoV-2-Infected Cells. *Stem Cell Reports*, **2021**, 16, 419-427	8	23
114	Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro		22
113	Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP). *PLoS ONE*, **2015**, 10, e0117152	3.7	21
112	Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. *Viruses*, **2021**, 13,	6.2	21
111	Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. *Journal of Hepatology*, **2017**, 67, 237-245	13.4	20
110	Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients. *Transplantation*, **2006**, 81, 808-9	1.8	20
109	Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies. *Journal of Clinical Medicine*, **2021**, 10,	5.1	20
108	Hepatitis C virus core antigen testing in liver and kidney transplant recipients. *Journal of Viral Hepatitis*, **2014**, 21, 769-79	3.4	19
107	Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration. *Journal of Viral Hepatitis*, **2011**, 18, 562-70	3.4	19
106	Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. *Journal of Viral Hepatitis*, **2008**, 15, 200-11	3.4	19
105	Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates.. *Cell Research*, **2022**,	24.7	19
104	48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection. *Journal of Hepatology*, **2020**, 73, S52-S53	13.4	18
103	Effects of cyclosporine on human dendritic cell subsets. *Transplantation Proceedings*, **2005**, 37, 20-4	1.1	17
102	COVID-19-Related Coagulopathy-Is Transferrin a Missing Link?. *Diagnostics*, **2020**, 10,	3.8	16
101	Clinical performance of SARS-CoV-2 IgG antibody tests and potential protective immunity		15
100	Novel multiple swab method enables high efficiency in SARS-CoV-2 screenings without loss of sensitivity for screening of a complete population. *Transfusion*, **2020**, 60, 2441-2447	2.9	14
99	Membranous Budd-Chiari syndrome in Caucasians. *Scandinavian Journal of Gastroenterology*, **2010**, 45, 226-34	2.4	14

98	Inhibition of papain-like protease PLpro blocks SARS-CoV-2 spread and promotes anti-viral immunity		14
97	Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. *Viruses*, **2021**, 13,	6.2	14
96	Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection. *Journal of Biological Chemistry*, **2021**, 297, 100925	5.4	14
95	A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. *European Journal of Immunology*, **2021**,	6.1	14
94	At-home self-testing of teachers with a SARS-CoV-2 rapid antigen test to reduce potential transmissions in schools		13
93	Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapy. *Reviews in Medical Virology*, **2016**, 26, 330-9	11.7	13
92	Characterization of the inhibition of hepatitis C virus entry by in vitro-generated and patient-derived oxidized low-density lipoprotein. *Hepatology*, **2013**, 57, 1716-24	11.2	12
91	Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area		12
90	Clinical Outcome and Viral Genome Variability of Hepatitis B Virus-Induced Acute Liver Failure. *Hepatology*, **2019**, 69, 993-1003	11.2	12
89	Cyclophilin polymorphism and virus infection. *Current Opinion in Virology*, **2015**, 14, 47-9	7.5	11
88	Prolonged survival of hepatitis C virus in the anesthetic propofol. *Clinical Infectious Diseases*, **2011**, 53, 963-4	11.6	11
87	Infectivity of deceased COVID-19 patients. *International Journal of Legal Medicine*, **2021**, 135, 2055-2060	3.1	11
86	Increased susceptibility of human endothelial cells to infections by SARS-CoV-2 variants. *Basic Research in Cardiology*, **2021**, 116, 42	11.8	11
85	Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation. *Antiviral Therapy*, **2019**, 24, 117-123	1.6	10
84	SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes		9
83	In vitro activity of itraconazole against SARS-CoV-2. *Journal of Medical Virology*, **2021**, 93, 4454-4460	19.7	9
82	Comparative analysis of point-of-care, high-throughput and laboratory-developed SARS-CoV-2 nucleic acid amplification tests (NATs). *Journal of Virological Methods*, **2021**, 291, 114102	2.6	9
81	Longitudinal Testing for Respiratory and Gastrointestinal Shedding of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Day Care Centers in Hesse, Germany. *Clinical Infectious Diseases*, **2021**, 73, e3036-e3041	11.6	9

80	Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings. *Medical Microbiology and Immunology*, **2021**, 210, 235-244	4	9
79	Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies. *Journal of Clinical Virology*, **2017**, 93, 46-52	14.5	8
78	Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. *International Journal of Infectious Diseases*, **2016**, 42, 1-3	10.5	8
77	The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virus. *PLoS ONE*, **2011**, 6, e24142	3.7	8
76	Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy. *Metabolites*, **2021**, 11,	5.6	8
75	Role of BK polyomavirus (BKV) and Torque teno virus (TTV) in liver transplant recipients with renal impairment. *Journal of Medical Microbiology*, **2018**, 67, 1496-1508	3.2	8
74	FACT- Frankfurt adjusted COVID-19 testing- a novel method enables high-throughput SARS-CoV-2 screening without loss of sensitivity		8
73	Surveillance of SARS-CoV-2 in Frankfurt am Main from October to December 2020 Reveals High Viral Diversity Including Spike Mutation N501Y in B.1.1.70 and B.1.1.7. *Microorganisms*, **2021**, 9,	4.9	8
72	Impact of immune suppressive agents on the BK-Polyomavirus non coding control region. *Antiviral Research*, **2018**, 159, 68-76	10.8	8
71	Methylene Blue Treatment of Grafts During Cold Ischemia Time Reduces the Risk of Hepatitis C Virus Transmission. *Journal of Infectious Diseases*, **2018**, 218, 1711-1721	7	8
70	Thirty years of CMV seroprevalence-a longitudinal analysis in a German university hospital. *European Journal of Clinical Microbiology and Infectious Diseases*, **2020**, 39, 1095-1102	5.3	7
69	Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus. *Viruses*, **2019**, 11,	6.2	7
68	Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. *Hepatology*, **2014**, 60, 508-20	11.2	7
67	Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. *Expert Review of Gastroenterology and Hepatology*, **2010**, 4, 63-79	4.2	7
66	A rare cause of nonalcoholic fatty liver disease. *Annals of Internal Medicine*, **2006**, 145, 154-5	8	7
65	SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission		7
64	A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. *Antiviral Research*, **2017**, 141, 116-123	10.8	6
63	Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors. *Viruses*, **2019**, 11,	6.2	6

62	Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes. *Cells*, **2020**, 9,	7.9	6
61	Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization. *Antiviral Research*, **2014**, 101, 37-44	10.8	6
60	The suppressive effect that myriocin has on hepatitis C virus RNA replication is independent of inhibition of serine palmitoyl transferase. *Journal of Infectious Diseases*, **2008**, 198, 1091-3	7	6
59	Optimized qRT-PCR approach for the detection of intra- and extra-cellular SARS-CoV-2 RNAs		6
58	Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication		6
57	Evaluation of a SARS-CoV-2 rapid antigen test: potential to help reduce community spread?		6
56	Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. *Gut*, **2016**, 65, 1015-23	19.2	6
55	Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure. *Frontiers in Immunology*, **2020**, 11, 534731	8.4	6
54	The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation. *Journal of Clinical Virology*, **2019**, 113, 14-19	14.5	5
53	Environmental Stability and Infectivity of Hepatitis C Virus (HCV) in Different Human Body Fluids. *Frontiers in Microbiology*, **2018**, 9, 504	5.7	5
52	HBV reactivation in allogeneic stem cell transplant recipients: Risk factors, outcome, and role of hepatitis B virus mutations. *Hepatology Communications*, **2017**, 1, 1014-1023	6	5
51	Anti-parietal cell autoantibodies (PCA) in primary biliary cirrhosis: a putative marker for recurrence after orthotopic liver transplantation?. *Annals of Hepatology*, **2010**, 9, 181-185	3.1	5
50	Lack of Antiviral Activity of Darunavir against SARS-CoV-2		5
49	Targeting pentose phosphate pathway for SARS-CoV-2 therapy		5
48	Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. *Cellular and Molecular Gastroenterology and Hepatology*, **2015**, 1, 285-294.e1	7.9	4
47	Comprehensive Evaluation of Hepatitis E Serology and Molecular Testing in a Large Cohort. *Pathogens*, **2020**, 9,	4.5	4
46	COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view. *Journal of Molecular Medicine*, **2021**, 1	5.5	4
45	Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication. *Frontiers in Microbiology*, **2021**, 12, 701198	5.7	4

44	Differentially conserved amino acid positions may reflect differences in SARS-CoV-2 and SARS-CoV behaviour. *Bioinformatics*, **2021**,	7.2	4
43	Clinical and Virological Aspects of HBV Reactivation: A Focus on Acute Liver Failure. *Viruses*, **2019**, 11,	6.2	3
42	Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells. *Antiviral Research*, **2015**, 124, 122-31	10.8	3
41	Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.. *Nephrology Dialysis Transplantation*, **2022**,	4.3	3
40	Severe impairment of T-cell responses to BNT162b2 immunization in multiple myeloma patients. *Blood*, **2021**,	2.2	3
39	Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	3
38	Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using minipools of RNA prepared from routine respiratory samples		3
37	Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings		3
36	In Vitro Activity of Itraconazole Against SARS-CoV-2		3
35	A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization. *Scientific Reports*, **2021**, 11, 11049	4.9	3
34	A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis. *Current Issues in Molecular Biology*, **2021**, 43, 1212-1225	2.9	3
33	SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment.. *Cell Discovery*, **2022**, 8, 42	22.3	3
32	Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA. *Journal of Medical Virology*, **2018**, 90, 282-290	19.7	2
31	Stability and transmission of hepatitis C virus in different anesthetic agents. *American Journal of Infection Control*, **2013**, 41, 942-3	3.8	2
30	Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. *Antiviral Research*, **2012**, 96, 51-8	10.8	2
29	RNA reference materials with defined viral RNA loads of SARS-CoV-2-A useful tool towards a better PCR assay harmonization.. *PLoS ONE*, **2022**, 17, e0262656	3.7	2
28	Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates		2
27	The COVID-19 PHARMACOME: A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization		2

26	Longitudinal testing for respiratory and gastrointestinal shedding of SARS-CoV-2 in day care centres in Hesse, Germany. Results of the SAFE KiDS Study		2
25	Typical symptoms of common otorhinolaryngological diseases may mask a SARS-CoV-2 infection. *European Archives of Oto-Rhino-Laryngology*, **2021**, 278, 3551-3558	3.5	2
24	Characterization of ACE Inhibitors and ATR Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model. *Life*, **2021**, 11,	3	2
23	COVID-19 among children seeking primary paediatric care with signs of an acute infection. *Acta Paediatrica, International Journal of Paediatrics*, **2021**, 110, 3315-3321	3.1	2
22	Powered air-purifying respirators used during the SARS-CoV-2 pandemic significantly reduce speech perception. *Journal of Occupational Medicine and Toxicology*, **2021**, 16, 43	2.7	2
21	Landscape of T-cell repertoires with public COVID-19-associated T-cell receptors in pre-pandemic risk cohorts. *Clinical and Translational Immunology*, **2021**, 10, e1340	6.8	2
20	Anti-parietal cell autoantibodies (PCA) in primary biliary cirrhosis: a putative marker for recurrence after orthotopic liver transplantation?. *Annals of Hepatology*, **2010**, 9, 181-5	3.1	2
19	Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures.. *Journal of Medical Virology*, **2022**,	19.7	2
18	Self-Collected Samples to Detect SARS-CoV-2: Direct Comparison of Saliva, Tongue Swab, Nasal Swab, Chewed Cotton Pads and Gargle Lavage.. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
17	Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response.. *Vaccines*, **2022**, 10,	5.3	2
16	Infectivity and stability of hepatitis C virus in different perfusion solutions. *Transplant Infectious Disease*, **2019**, 21, e13135	2.7	1
15	Characterization of the humoral immune response to BNT162b2 in elderly residents of long-term care facilities five to seven months after vaccination		1
14	Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. *PLoS ONE*, **2021**, 16, e0258684	3.7	1
13	CD47 as a potential biomarker for the early diagnosis of severe COVID-19		1
12	SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. *Journal of Hepatology*, **2019**, 70, 603-614	13.4	1
11	Pediatrics and COVID-19. *Advances in Experimental Medicine and Biology*, **2021**, 1318, 197-208	3.6	1
10	Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. *Journal of Clinical Virology*, **2021**, 142, 104932	14.5	1
9	Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma.. *Cancer Cell*, **2022**,	24.3	1

8	Expression Cloning of Host Factors Required for the HCV Replication Cycle. *Methods in Molecular Biology*, **2019**, 1911, 169-182	1.4	0
7	Efficient inactivation of pseudotyped HIV-based lentiviral vectors and infectious HIV. *Journal of Virological Methods*, **2020**, 276, 113768	2.6	0
6	High-Frequency Self-Testing by Schoolteachers for Sars-Cov-2 Using a Rapid Antigen Test. *Deutsches Ärzteblatt International*, **2021**, 118, 252-253	2.5	0
5	Virale Infektionen bei Lebertransplantierten. *Gastroenterologe*, **2020**, 15, 227-234	0.1	
4	Relevance of Resistance Against Direct Acting Antiviral Agents in Hepatitis C Virus Infection What Technology do we Really Need in Clinical Practice?. *Current Hepatitis Reports*, **2013**, 12, 195-199		
3	Aktueller Stand der Lebertransplantation. *Gastroenterologe*, **2013**, 8, 35-40	0.1	
2	Virale Infektionen bei Lebertransplantierten. *Wiener Klinisches Magazin: Beilage Zur Wiener Klinischen Wochenschrift*, **2020**, 23, 240-245	0	
1	Call for a pan-European COVID-19 response must be comprehensive - AuthorsTreply. *Lancet, The*, **2021**, 397, 1541	40	